Branded Products

Rx Products

Mylan Specialty, formerly known as Dey Pharma, focuses on the development, manufacturing and marketing of prescription drug products for respiratory diseases, life-threatening allergic reactions, and psychiatric disorders.

Please visit Mylan Specialty for more information about our brand name product portfolio.

  • EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors

    EpiPen® (epinephrine) 0.3 mg and EpiPen Jr® (epinephrine) 0.15 mg Auto-Injectors are for the emergency treatment of life-threatening allergic reactions (anaphylaxis) caused by allergens, exercise, or unknown triggers; and for people who are at increased risk for these reactions. EpiPen and EpiPen Jr are intended for immediate self administration as emergency supportive therapy only. Seek immediate emergency medical treatment after use.

    Important Safety Information
    EpiPen Auto-Injectors contain a single dose of epinephrine, which you inject into your outer thigh. DO NOT INJECT INTO YOUR VEIN, BUTTOCK, FINGERS, TOES, HANDS OR FEET. In case of accidental injection, please seek immediate medical treatment. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.

    Tell your doctor if you have certain medical conditions such as asthma, depression, thyroid disease, Parkinson’s disease, diabetes, high blood pressure and heart disease, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Be sure to also tell your doctor all the medicines you take, especially medicines for asthma. If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have longer lasting side effects when you take the EpiPen or EpiPen Jr Auto-Injector.

    The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness or anxiety. These side effects usually go away quickly, especially if you rest.

    Talk to your health care professional to see if EpiPen® or EpiPen Jr® Auto-Injector is right for you.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

  • PERFOROMIST® (formoterol fumarate) Inhalation Solution

    PERFOROMIST® (formoterol fumarate) Inhalation Solution is used for the long-term treatment of chronic obstructive pulmonary disease (COPD) including chronic inflammation of the lungs (bronchitis) and emphysema. It is only to be used with a jet nebulizer and is taken twice daily (morning and evening). 

    Important Limitations for Use:

    • PERFOROMIST should not be used as a rescue medication
    • PERFOROMIST is not indicated to treat asthma. The safety and effectiveness of PERFOROMIST Inhalation Solution in asthma has not been established.


    PERFOROMIST Inhalation Solution belongs to a class of drugs called long-acting beta2-agonists (LABA). People with asthma who take LABA such as PERFOROMIST Inhalation Solution have an increased risk of death from asthma problems. Do not use PERFOROMIST Inhalation Solution if you have asthma without using a long-term asthma control medicine.

    Warnings and Precautions
    PERFOROMIST Inhalation Solution should not be used instead of rescue inhaler or nebulized medicine for the treatment of acute symptoms. Extra doses of PERFOROMIST Inhalation Solution should not be used for that purpose since overuse can cause serious heart problems, including death. Acute or sudden symptoms should be treated with an inhaled short-acting beta2-agonist.

    Seek immediate medical attention if: 
    • your symptoms quickly worsen despite recommended doses of PERFOROMIST Inhalation Solution
    • PERFOROMIST Inhalation Solution treatment becomes less effective
    • you need more inhalations of a short-acting beta2-agonist (rescue inhaler or nebulized medicine) than usual.
    Do not use PERFOROMIST Inhalation Solution with other LABA medicines for any reason.

    Co-existing Conditions
    The use of PERFOROMIST Inhalation Solution with certain health conditions or with certain medications can cause serious side effects. Tell your health care professional about all of your health conditions, including if you:

    • have heart problems
    • have high blood pressure
    • have diabetes
    • have seizures
    • have thyroid problems
    • have liver problems
    • are pregnant or planning to become pregnant. It is not known if PERFOROMIST Inhalation Solution can harm an unborn baby.
    • are breastfeeding. It is not known if PERFOROMIST Inhalation Solution passes into breast milk and if it can harm your baby.

    Drug Interactions
    It is important to inform your healthcare professional of all prescription or over the counter medications you are taking including: beta-blockers, some antidepressants (tricyclic and MAO inhibitors), steroids, diuretics, xanthine derivatives (e.g. theophylline), as well as vitamins and herbal supplements. PERFOROMIST Inhalation Solution and certain medicines may interact with each other and cause serious side effects.

    Immediate allergic reactions may occur after taking PERFOROMIST Inhalation Solution, including anaphylactic reactions, hives, generalized swelling including the airway, rash, and bronchospasm.

    Side Effects
    The most common side effects reported in patients taking PERFOROMIST Inhalation Solution were diarrhea, nausea, nasopharyngitis, dry mouth, dizziness, and insomnia. Serious side effects may include sudden shortness of breath, serious allergic reactions, chest pain, increased or decreased blood pressure, a fast and irregular heartbeat, low blood potassium, high blood sugar, and high blood acid.

    How to Use PERFOROMIST Inhalation Solution
    Use PERFOROMIST Inhalation Solution exactly as directed by your health care professional. Do not stop using PERFOROMIST Inhalation Solution or other medicines to control or treat your COPD unless told to do so by your health care professional because your symptoms might get worse. Your health care professional will change your medicines as needed.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

    EMSAM® (selegiline transdermal system) is a skin patch used to treat major depressive disorder.

    Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, teens, and young adults. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. EMSAM is not approved for use in children under 18.


      What is the most important information I should know about EMSAM?
    • Antidepressants may increase suicidal thoughts or actions in children, teenagers and young adults
    • Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts or feelings. This is very important when an antidepressant is started or when the dose is changed
    • Call a healthcare provider right away to report any new or sudden changes in mood, behavior, thoughts, or feelings
    • EMSAM Transdermal System is not approved for use in patients under 18 years of age
    • Call a healthcare provider right away if you or someone you care for have any of the following symptoms, especially if they are new, worse, or worry you:
      Thoughts about suicide or dying; attempts to commit suicide; new or worse depression, anxiety or irritability; feeling very agitated or restless; panic attacks; trouble sleeping; acting aggressive, being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking; other unusual changes in behavior or mood.
    1. Do not eat or drink foods and beverages with high amounts of a substance called tyramine while on EMSAM 9 mg/24 hr or 12 mg/24 hr, and for 2 weeks after stopping these doses. Ask your healthcare professional or see the Medication Guide for a complete list of foods and drinks that must be avoided. EMSAM at any dose should not be used in children under 12 even when used with dietary modifications.
      • Consuming tyramine-rich foods and beverages can lead to a sudden, large increase in blood pressure called “hypertensive crisis.” This is a serious medical condition that may be life-threatening. Seek immediate medical care if you experience any of these symptoms: sudden severe headache, nausea, stiff neck, vomiting, a fast or slow heartbeat or a change in the way your heart beats (palpitations), tight chest pain, a lot of sweating, confusion, dilated pupils, and sensitivity to light.
    2. Tell your doctor about all medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Tell all of your healthcare professionals that you are using EMSAM.
      • Due to the potential for serious and life-threatening side effects, do not use the following medicines while using EMSAM at any dose, and for 2 weeks after stopping EMSAM:
        • Other medicines to treat depression (antidepressants) including other MAOI medicines; medicines which contain selegiline (such as Eldepryl®); St. John’s Wort; narcotic pain medicines that contain meperidine e.g., Demerol®; pain medicines tramadol, methadone, or propoxyphene; medicines containing carbamazepine e.g., Tegretol® a seizure medicine and oxcarbazepine, e.g., Trileptal® a seizure medicine; cold/cough preparations, decongestants, over-the-counter diet pills or herbal weight-loss products containing pseudoephedrine, phenylephrine, phenylpropanolamine, dextromethorphan, or ephedrine; herbal or dietary supplements that contain tyramine; Flexeril® (cyclobenzaprine), a medicine used to treat muscle spasms; amphetamines (stimulants or “uppers”); and BuSpar® (buspirone), an anxiety medicine
        • Some of these medicines will have to be stopped for 1 week (or more) before you can start using EMSAM

      What should I tell my doctor before starting EMSAM Transdermal System?
    • Tell your healthcare professional about any medical conditions, including if you:
      • Have or had manic episodes (a mental condition that causes “high” moods)
      • Have any heart problems
      • Have or had seizures (convulsions or “fits”)
      • Tend to get dizzy or faint
      • Are planning to have surgery
      • Are or intend to become pregnant
      • Are breast-feeding
      What are the possible side effects of EMSAM Transdermal System?
    • EMSAM may worsen your depression, give you suicidal thoughts, or cause unusual changes in behavior. Call your healthcare professional right away if you feel worse with EMSAM
    • EMSAM may cause mania or hypomania in people who have a history of mania
    • EMSAM may cause low blood pressure. Lie down if you feel dizzy, faint, or lightheaded and change positions gradually
    • The most common side effect of EMSAM is a skin irritation where the patch is placed. Other common side effects with EMSAM include: headache, difficulty sleeping, diarrhea, dry mouth
      How should I use EMSAM Transdermal System?
    • Use EMSAM exactly as prescribed and do not stop or change treatment (even if you start to feel better) without talking to your health care professional
    • Use only one patch at a time and change the patch once a day (every 24 hours). If you use more than one EMSAM patch at a time, remove the patches right away and call your doctor or Poison Control at 1-800-222-1222
      General advice about EMSAM Transdermal System
    • Avoid exposing the EMSAM application site to direct heat, such as heating pads, electric blankets, heat lamps, saunas, hot tubs, heated water beds, and prolonged direct sunlight
    • Do not drive or operate hazardous machinery until you know how EMSAM affects you as EMSAM can reduce your judgment, ability to think, or coordination. Avoid drinking alcohol while using EMSAM
    • Do not use EMSAM if you are allergic to anything in EMSAM. See the Medication Guide for a complete list of ingredients in EMSAM
    • If you have any questions about your health or medicines, talk to your health care professional

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

  • EasiVent®

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

    Please click here for full instructions for Use with Metered-Dose Inhalers

    EasiVent is available by prescription only.

    ULTIVA is indicated for intravenous administration:

    • As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures
    • For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting
    • As an analgesic component of monitored anesthesia care in adult patients

    Continuous infusions of ULTIVA should be administered only by an infusion device. IV bolus administration of ULTIVA should be used only during the maintenance of general anesthesia. In nonintubated patients, single doses of ULTIVA should be administered over 30 to 60 seconds. Interruption of an infusion of ULTIVA will result in rapid offset of effect. Rapid clearance and lack of drug accumulation result in rapid dissipation of respiratory depressant and analgesic effects (within 5 to 10 min) upon discontinuation of ULTIVA at recommended doses. Discontinuation of an infusion of ULTIVA should be preceded by the establishment of adequate postoperative analgesia particularly where postoperative pain is anticipated.

    Vital signs and oxygenation must be continually monitored during ULTIVA administration. ULTIVA produces adverse events that are characteristic of μ-opioids, such as respiratory depression, tachycardia, bradycardia, hypotension, and skeletal muscle (including chest wall) rigidity. Because these effects are dose-dependent and can occur rapidly, continual monitoring is necessary. ULTIVA should not be used as a sole agent because loss of consciousness cannot be assured and because of a high incidence of apnea, muscle rigidity, and tachycardia.

    ULTIVA should be used with caution in pediatric, geriatric, and morbidly obese patients due to high variability in pharmacodynamics and dose/response. Intraoperative awareness has been reported with concomitant administration with propofol infusion ≤75 mcg/kg/min.

    Failure to adequately clear the IV tubing to remove residual ULTIVA has been associated with the appearance of respiratory depression, apnea, and muscle rigidity upon the administration of additional fluids or medications through the same IV tubing.

    Due to the presence of glycine in the formulation, ULTIVA is contraindicated for epidural or intrathecal administration. ULTIVA is also contraindicated in patients with known hypersensitivity to fentanyl analogs.


    Please see full Prescribing Information for all precautions, warnings, contraindications, and adverse events.

    Remifentanil is commonly referred to as Remi by anesthesia providers.

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

Mylan Specialty

Mylan acquired Dey Pharma in 2007. Since then, we’ve continued to develop and manufacture high quality specialty products.

Grants and Donations

We proudly support a wide range of clinical, therapeutic and educational initiatives.

How to apply

EpiPen®, EpiPen Jr®, EpiPen 2-Pak® and EpiPen Jr 2-Pak® are registered trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Mylan Specialty L.P. 

PERFOROMIST® and EasiVent® are registered trademarks of Mylan Specialty L.P.

EMSAM® is a registered trademark of Somerset Pharmaceuticals, Inc. EMSAM is manufactured for Somerset Pharmaceuticals, Inc. by Mylan Technologies, Inc., and is distributed by Mylan Specialty L.P.

ULTIVA® is a registered trademark of Glaxo Group Limited.

Mylan and Mylan logo are registered trademarks of Mylan, Inc.
Last Updated:  22/03/2017